Gilead Sciences Inc. (GILD) Shares Sold by Founders Capital Management LLC
Founders Capital Management LLC lowered its position in shares of Gilead Sciences Inc. (NASDAQ:GILD) by 9.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,066 shares of the biopharmaceutical company’s stock after selling 1,850 shares during the period. Founders Capital Management LLC’s holdings in Gilead Sciences were worth $1,429,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in GILD. Advisory Services Network LLC raised its position in Gilead Sciences by 7.5% in the third quarter. Advisory Services Network LLC now owns 37,128 shares of the biopharmaceutical company’s stock valued at $2,938,000 after buying an additional 2,605 shares during the period. Trust Co. of Oklahoma raised its position in Gilead Sciences by 10.1% in the third quarter. Trust Co. of Oklahoma now owns 6,467 shares of the biopharmaceutical company’s stock valued at $512,000 after buying an additional 593 shares during the period. Lawson Kroeker Investment Management Inc. NE raised its position in Gilead Sciences by 23.9% in the third quarter. Lawson Kroeker Investment Management Inc. NE now owns 129,329 shares of the biopharmaceutical company’s stock valued at $10,233,000 after buying an additional 24,975 shares during the period. Founders Financial Securities LLC acquired a new position in Gilead Sciences during the third quarter valued at about $845,000. Finally, F&V Capital Management LLC raised its position in Gilead Sciences by 3.7% in the third quarter. F&V Capital Management LLC now owns 78,410 shares of the biopharmaceutical company’s stock valued at $6,204,000 after buying an additional 2,775 shares during the period. 73.59% of the stock is owned by institutional investors and hedge funds.
Gilead Sciences Inc. (NASDAQ:GILD) traded down 1.19% during trading on Monday, reaching $74.54. Gilead Sciences Inc. has a 1-year low of $71.39 and a 1-year high of $107.38. The firm’s 50-day moving average price is $74.54 and its 200 day moving average price is $80.07. The firm has a market cap of $98.20 billion, a P/E ratio of 6.89 and a beta of 1.25.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, November 1st. The biopharmaceutical company reported $2.75 earnings per share for the quarter, missing analysts’ consensus estimates of $2.87 by $0.12. The business had revenue of $7.40 billion for the quarter, compared to the consensus estimate of $7.47 billion. Gilead Sciences had a return on equity of 100.57% and a net margin of 47.74%. Gilead Sciences’s revenue for the quarter was down 9.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.22 EPS. On average, analysts anticipate that Gilead Sciences Inc. will post $11.47 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 29th. Shareholders of record on Thursday, December 15th will be given a dividend of $0.47 per share. The ex-dividend date is Tuesday, December 13th. This represents a $1.88 dividend on an annualized basis and a yield of 2.53%. Gilead Sciences’s dividend payout ratio is presently 17.44%.
ILLEGAL ACTIVITY WARNING: “Gilead Sciences Inc. (GILD) Shares Sold by Founders Capital Management LLC” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2016/11/29/gilead-sciences-inc-gild-shares-sold-by-founders-capital-management-llc.html.
Several analysts have weighed in on the stock. Jefferies Group upped their price objective on shares of Gilead Sciences from $91.00 to $93.00 and gave the stock a “buy” rating in a research note on Wednesday, October 5th. Piper Jaffray Cos. reaffirmed a “buy” rating and set a $108.00 price objective on shares of Gilead Sciences in a research note on Monday, August 15th. Berenberg Bank assumed coverage on shares of Gilead Sciences in a research note on Thursday, September 22nd. They set a “buy” rating on the stock. Stifel Nicolaus assumed coverage on shares of Gilead Sciences in a research note on Monday, November 14th. They set a “buy” rating and a $100.00 price objective on the stock. They noted that the move was a valuation call. Finally, Zacks Investment Research cut shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, September 6th. Ten analysts have rated the stock with a hold rating, nineteen have given a buy rating and two have issued a strong buy rating to the company’s stock. Gilead Sciences currently has a consensus rating of “Buy” and an average price target of $97.90.
In other Gilead Sciences news, Director John W. Madigan sold 105,000 shares of the stock in a transaction dated Friday, November 18th. The shares were sold at an average price of $74.86, for a total transaction of $7,860,300.00. Following the completion of the transaction, the director now owns 121,761 shares in the company, valued at $9,115,028.46. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider John F. Milligan sold 70,000 shares of the stock in a transaction dated Tuesday, September 6th. The stock was sold at an average price of $77.74, for a total transaction of $5,441,800.00. Following the transaction, the insider now owns 1,128,963 shares of the company’s stock, valued at approximately $87,765,583.62. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.